OphtAI, a joint-venture between two key industrials, aims at revolutionizing the screening and diagnostic of eye pathologies thanks to its state-of-the-art solution based on artificial intelligence.
OphtAI is the fruit of an incredible association of various experts (researchers, clinicians and industrials) committed for many years in innovative and ambitious research projects to optimize the organization of eye care.
With OphtAI, we aim to democratize expertise to encourage the prevention of eye disease, and to facilitate screening and diagnosis. Our Artificial Intelligence, with unrivaled performance levels, is designed for:
- specialists, to support them in their practice, making them more efficient;
- integrators and distributors, to enhance their offer and bring them to the cutting edge of technology;
- researchers, to help them move forward with their projects.
OphtAI technology for eye care professionals
OphtAI for industrials
Research and clinical trials
Pr Pascale MASSIN, retina expert, President of the CFSR
Screening: the latest challenges
The eye diseases that cause blindness are silent and common. They could affect more than a billion people over the coming decade. The current lack of ophthalmologists means that we must find alternative solutions to identify the patients likely to lose their sight as early as possible, in order to offer them every chance of slowing down the disease, if not avoiding it altogether.
OphtAI RD : an efficient application using our technology
OphtAI RD is our screening artificial Intelligence for diabetic retinopathy; it performs as well as the best retina experts and its published results are the best in the world. It results from a collaborative project involving top clinical specialists and scientific laboratories.
Watch our interview of OphtAI’s CEO, @Alexandre le Guilcher, during the @Arab Health congress. : “From a retina photo, AI will analyze and assess a level of disease risk, in this way allowing a massive screening of the population. OphtAI is a tested technology...
In January 2020, Philippe Blanco joined the Evolucare group as Chief Executive Officer. In his role, Philippe will lead Evolucare Group’s growth in France and internationally…
OphtAI, is the winner of the “Grand Prix de l’Innovation” of the French Society of Telemedicine. Thank to the…
Need more information ?
OphtAI is a Joint Venture specialized in Artificial Intelligence for Eye Care. Would you like to find out more about our solutions or meet our teams?